Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/591696
Germany Pharmaceuticals & Healthcare Report Q1 2008
Description:
The Germany Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Germanys pharmaceuticals and healthcare industry.
The German drug market should grow at a rate of 3.19% between 2007-2012, with OTC drugs and the expansion of the generic sector being the main drivers of growth. Consumer health products should reach a value of US$8.5bn by 2012, due to increasing competition and the emergence of the internet as a major sales channel.
The European Commission (EC) is currently challenging restrictive pharmacy ownership laws in a number of countries, with companies like Germany’s Schlecker keenly awaiting the outcome. The retailer, which sells non-medicinal consumer health products in Germany, has recently opened an online pharmacy in the Netherlands, offering over 600 OTC products. Presently, Germany only allows selfemployed pharmacists to run pharmacies, preventing chains from entering the market. However, Schlecker is looking to circumvent this by running a mail order operation through its Dutch store.
Elsewhere, plans to create a new drug approvals body in Germany have collapsed after the coalition parties in the government failed to agree on a framework for the agency, exemplifying how political infighting can de-rail reform initiatives. The new institution, provisionally called DAMA, would have replaced the current Federal Institute for Drugs and Medical Devices (BfArM), increasing the efficiency of the approvals process, which is beset by delays.
Meanwhile, Germany takes 2nd place in the revised Business Environment Rankings for the Western European region. We have completely overhauled the methodology giving greater weight to regulatory factors affecting the drug market, while utilising a more nuanced analysis of country-specific economic and political factors. Germany’s position derives mainly from its strong country indicators with impressive scores in areas such as policy continuity and lack of corruption. The ratings also favour larger markets, which gives Germany a further advantage, due to its high per-capita expenditure on pharmaceuticals. However, sluggish growth is having a negative impact and the author does not envisage Germany closing the gap on regional leader Switzerland over the forecast period.
The German drug market should grow at a rate of 3.19% between 2007-2012, with OTC drugs and the expansion of the generic sector being the main drivers of growth. Consumer health products should reach a value of US$8.5bn by 2012, due to increasing competition and the emergence of the internet as a major sales channel.
The European Commission (EC) is currently challenging restrictive pharmacy ownership laws in a number of countries, with companies like Germany’s Schlecker keenly awaiting the outcome. The retailer, which sells non-medicinal consumer health products in Germany, has recently opened an online pharmacy in the Netherlands, offering over 600 OTC products. Presently, Germany only allows selfemployed pharmacists to run pharmacies, preventing chains from entering the market. However, Schlecker is looking to circumvent this by running a mail order operation through its Dutch store.
Elsewhere, plans to create a new drug approvals body in Germany have collapsed after the coalition parties in the government failed to agree on a framework for the agency, exemplifying how political infighting can de-rail reform initiatives. The new institution, provisionally called DAMA, would have replaced the current Federal Institute for Drugs and Medical Devices (BfArM), increasing the efficiency of the approvals process, which is beset by delays.
Meanwhile, Germany takes 2nd place in the revised Business Environment Rankings for the Western European region. We have completely overhauled the methodology giving greater weight to regulatory factors affecting the drug market, while utilising a more nuanced analysis of country-specific economic and political factors. Germany’s position derives mainly from its strong country indicators with impressive scores in areas such as policy continuity and lack of corruption. The ratings also favour larger markets, which gives Germany a further advantage, due to its high per-capita expenditure on pharmaceuticals. However, sluggish growth is having a negative impact and the author does not envisage Germany closing the gap on regional leader Switzerland over the forecast period.
Contents:
Executive Summary 5
Germany Pharmaceuticals And Healthcare Industry SWOT 6
Germany Political SWOT 7
Germany Economic SWOT 7
Pharmaceutical Business Environment Ratings 8
Pharmaceutical Ratings - Revised Methodology 8
Ratings Overview 8
Table: Pharmaceutical Business Environment Indicators 9
Weighting 10
Table: Weighting Of Components 10
Germany -Business Environment Rating 11
Limits To Potential Returns 11
Risks To Realisation Of Returns 12
Western Europe Overview 13
Germany - Market 15
Regulatory Regime17
Intellectual Property Developments 18
Pricing And Reimbursement Issues 20
Retail Industry 22
Industry Developments25
Healthcare Sector 25
Pharmaceutical Sector 27
Domestic Industry 28
Krankenkassen 34
Foreign Industry 34
Research And Development Sector 38
Generics Sector 39
Wholesaler Sector 42
Epidemiology 43
Biotechnology Sector 43
Industry Forecast Scenario 46
Overall Market Forecast 46
Table: German Drug Market Expenditure Forecasts 47
Key Growth Factors - Industry 48
Table: German Health Expenditure Forecast Indicators 48
Key Growth Factors - Macroeconomic 50
Table: Germany - Macroeconomic Forecasts 52
Prescription Market Forecast 53
Table: Germany’s Prescription Drugs Market Forecast Indicators (US$mn unless otherwise stated) 54
OTC Market Forecast 55
Table: German OTC Market Forecast Indicators (US$mn unless otherwise stated) 56
Generics And Branded Market Forecasts 57
Table: Germany’s Generics And Branded Market Forecast Indicators 58
Export/Import Forecasts 59
Table: Germany’s Pharmaceuticals Exports And Imports Forecasts (US$mn) 60
Key Risks To our Forecast Scenario 61
Competitive Landscape62
Company Profiles63
GlaxoSmithKline 63
Pfizer 65
Novartis 67
Sanofi-Aventis 69
Merck & Co 71
Bayer 73
Boehringer Ingelheim 76
BMI Forecast Modelling80
How We Generate Our Industry Forecasts 80
Pharmaceutical Industry 81
Sources 81
Germany Pharmaceuticals And Healthcare Industry SWOT 6
Germany Political SWOT 7
Germany Economic SWOT 7
Pharmaceutical Business Environment Ratings 8
Pharmaceutical Ratings - Revised Methodology 8
Ratings Overview 8
Table: Pharmaceutical Business Environment Indicators 9
Weighting 10
Table: Weighting Of Components 10
Germany -Business Environment Rating 11
Limits To Potential Returns 11
Risks To Realisation Of Returns 12
Western Europe Overview 13
Germany - Market 15
Regulatory Regime17
Intellectual Property Developments 18
Pricing And Reimbursement Issues 20
Retail Industry 22
Industry Developments25
Healthcare Sector 25
Pharmaceutical Sector 27
Domestic Industry 28
Krankenkassen 34
Foreign Industry 34
Research And Development Sector 38
Generics Sector 39
Wholesaler Sector 42
Epidemiology 43
Biotechnology Sector 43
Industry Forecast Scenario 46
Overall Market Forecast 46
Table: German Drug Market Expenditure Forecasts 47
Key Growth Factors - Industry 48
Table: German Health Expenditure Forecast Indicators 48
Key Growth Factors - Macroeconomic 50
Table: Germany - Macroeconomic Forecasts 52
Prescription Market Forecast 53
Table: Germany’s Prescription Drugs Market Forecast Indicators (US$mn unless otherwise stated) 54
OTC Market Forecast 55
Table: German OTC Market Forecast Indicators (US$mn unless otherwise stated) 56
Generics And Branded Market Forecasts 57
Table: Germany’s Generics And Branded Market Forecast Indicators 58
Export/Import Forecasts 59
Table: Germany’s Pharmaceuticals Exports And Imports Forecasts (US$mn) 60
Key Risks To our Forecast Scenario 61
Competitive Landscape62
Company Profiles63
GlaxoSmithKline 63
Pfizer 65
Novartis 67
Sanofi-Aventis 69
Merck & Co 71
Bayer 73
Boehringer Ingelheim 76
BMI Forecast Modelling80
How We Generate Our Industry Forecasts 80
Pharmaceutical Industry 81
Sources 81
Companies Mentioned
- Bayer
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck & Co
- Novartis
- Pfizer
- Sanofi-Aventis
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Friday, May 24, 2013
10:05:16 AM
10:05:16 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Germany Pharmaceuticals & Healthcare Report Q1 2008
Web Address
http://www.researchandmarkets.com/reports/591696
Office Code
OC8DIQSNPPUUUV
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Single User |
|
EURO€ 874.00 |
|---|
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Friday, May 24, 2013
10:05:16 AM
10:05:16 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp